Cargando…
Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy
PURPOSE: Gephyrin (GPHN) is an essential protein in the regulation of inhibitory postsynaptic density and polymorphism in the corresponding gene may have a role in the development of pharmacoresistant epilepsy (PRE). For the first time, we aimed to evaluate the association of rs928553T/C variants wi...
Autores principales: | El-Tallawy, Hamdy N, Abuhamdah, Sawsan, Nassar, Ahmed Y, Farghaly, Wafaa M A, Saleem, Tahia H, Atta, Sara A, Sayed, Ayat A, Tohamy, Amal M, Hassan, Mohammed H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437390/ https://www.ncbi.nlm.nih.gov/pubmed/34526803 http://dx.doi.org/10.2147/PGPM.S327808 |
Ejemplares similares
-
Spectrum of epilepsy – prevalence, impact, and treatment gap: an epidemiological study from Al-Quseir, Egypt
por: El-Tallawy, Hamdy N, et al.
Publicado: (2016) -
Cortical stimulation in pharmacoresistant focal epilepsies
por: Ellrich, Jens
Publicado: (2020) -
Genetic variations associated with pharmacoresistant epilepsy
por: Cárdenas-Rodríguez, Noemí, et al.
Publicado: (2020) -
Construction and Standardization of Dementia Arabic Scale
por: Farghaly, Wafaa M, et al.
Publicado: (2021) -
Clinical and biochemical study of d-serine metabolism among schizophrenia patients
por: El-Tallawy, Hamdy N, et al.
Publicado: (2017)